TY - JOUR T1 - Nebulised colistimethate sodium improves quality of life in patients with bronchiectasis colonised by <em>pseudomonas aeruginosa</em> JF - European Respiratory Journal JO - Eur Respir J VL - 42 IS - Suppl 57 SP - P2732 AU - Charles Haworth AU - Diana Bilton AU - Robert Kenyon Y1 - 2013/09/01 UR - http://erj.ersjournals.com/content/42/Suppl_57/P2732.abstract N2 - Pseudomonas aeruginosa (P. aeruginosa) colonisation has a negative quality of life (QoL) impact in patients with bronchiectasis. 1 To date there is little published work on the long term effects of inhaled antibiotics on QoL in this population.We conducted a randomised, double-blind, controlled study to investigate the efficacy of ≤6 months nebulised CMS in patients with non-cystic fibrosis bronchiectasis colonised by susceptible P. aeruginosa [ISRCTN49790596]. Patients self-administered CMS (Promixin; 1 MIU/mL) or placebo (0.45% saline), twice daily via an I-neb AAD System. Here we report QoL results, measured with St. George’s Respiratory Questionnaire (SGRQ). SGRQ assesses QoL across 3 domains (symptoms, activity, impact) and was administered at weeks 0, 12, and 26.Patients with &lt;80% compliance were excluded from analysis, leaving: n=54 (weeks 0 &amp; 12); n=31 (week 26), for each arm. Total mean % SGRQ (Table 1), and mean changes from baseline per SGRQ domain (Table 2) are reported.View this table:Table 1. Mean SGRQ (%).View this table:Table 2. Mean Δ baseline (%).The significant QoL improvement with CMS, compared with placebo (p=0.018), was primarily due to significant improvements in symptoms (p=0.001) and impact (p=0.008) domains.These results indicate that patients with bronchiectasis colonised by P. aeruginosa benefit from dramatic improvements in QoL when treated with CMS delivered via the I-neb AAD System.1. Wilson et al. Eur Respir J. 1997;10:1754-1760. ER -